



Order: SAMPLE REPORT

Client #: 12345

Doctor: Sample Doctor, MD

Doctors Data Inc. 3755 Illinois Ave. St. Charles, IL 60174 Patient: Sample Report

Age: 41 Sex: Female

Body Mass Index (BMI): N/A


Menopausal Status: Pre-Menopausal

Sample Collection Date/Time Date Collected 10/01/2018

AM30 10/01/2018 0800

Date Received 10/03/2018 **Date Reported** 10/05/2018

Analyte	Result	Unit	L	WRI	Н	Optimal Range	Reference Interval
Cortisol AM30	8.5	nmol/L	<	>		14.0 - 25.0	5.1 - 30.0
DHEA*	110	pg/mL		\rightarrow			106 - 300



Hormone Comments:

 Suboptimal AM cortisol level and reported symptoms are suggestive of HPA axis (adrenal gland) dysfunction. The current samples are routinely held three weeks from receipt for additional testing.

Notes:

RI= Reference Interval, L (blue)= Low (below RI), WRI (green)= Within RI (optimal), WRI (yellow)= Within RI (not optimal), H (red)= High (above RI) The current samples are routinely held three weeks from receipt for additional testing.

*This test was developed and its performance characteristics determined by Doctor's Data, Inc. The FDA has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Methodology: Enzyme Immunoassay



Order: SAMPLE REPORT

Client #: 12345

Doctor: Sample Doctor, MD

Doctors Data Inc. 3755 Illinois Ave. St. Charles, IL 60174 Patient: Sample Report

Age: 41 Sex: Female

Body Mass Index (BMI): N/A

Menopausal Status: Pre-Menopausal

 Sample Collection
 Date/Time

 Date Collected
 10/01/2018

 AM30
 10/01/2018 0800

 Date Received
 10/03/2018

 Date Reported
 10/05/2018

Analyte	Result	Unit	L	WRI	Н	Reference Interval	Supplementation Range**
Estradiol (E2)	1.5	pg/mL		\rightarrow		0.5 - 5.0	1.5 - 7.2
Progesterone (Pg)	73	pg/mL	1			127 - 446	500 - 3000
Pg/E2 Ratio	48.7		1			200 - 600	
Testosterone	35	pg/mL				6.0 - 49	30 - 60
DHEA*	110	pg/mL				106 - 300	



Hormone Comments:

Progesterone to estradiol (Pg/E2) ratio and reported symptoms are consistent with progesterone insufficiency (estrogen dominance).
 Supplementation with topical progesterone to correct this relative deficiency is a consideration. Note: The progesterone level is suggestive of an anovulatory cycle, luteal phase failure or collection outside of luteal phase.

Notes:

RI= Reference Interval, L (blue) = Low (below RI), WRI (green) = Within RI (optimal), WRI (yellow) = Within RI (not optimal), H (red) = High (above RI) The current samples are routinely held three weeks from receipt for additional testing.

The Pg/E2 ratio is an optimal range established based on clinical observation. Progesterone supplementation is generally required to achieve this level in men and postmenopausal women.

*This test was developed and its performance characteristics determined by Doctor's Data, Inc. The FDA has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

**If supplementation is reported then the supplementation ranges will be graphed. The supplementation ranges depicted are for informational purposes only and were derived from a cohort of adult men and women utilizing physiologic transdermal bioidentical hormone therapy.